Clinical Data Lilly debuts more Foundayo data as FDA requests post-marketing trials Pharmaceutical TechnologyThe FDA requires Eli Lilly to evaluate "unexpected serious" risks associated with Foundayo - some of which have been addressed by the ACHIEVE-4 trial.Clinical DataMetabolic & GLP-1Read full story pharminent April 16, 2026 (Last updated: April 16, 2026) Pharmaceutical Technology The FDA requires Eli Lilly to evaluate “unexpected serious” risks associated with Foundayo – some of which have been addressed by the ACHIEVE-4 trial. Clinical DataMetabolic & GLP-1Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Roche to start new Elevidys study following setback in EuropeNext: Lilly’s new obesity pill passes heart safety test in diabetes Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
